Literature DB >> 8965173

Measurement of regional cerebral plasma pool and hematocrit with copper-62-labeled HSA-DTS.

H Okazawa1, Y Yonekura, Y Fujibayashi, H Yamauchi, K Ishizu, S Nishizawa, Y Magata, N Tamaki, H Fukuyama, A Yokoyama, J Konishi.   

Abstract

UNLABELLED: We developed copper-62-labeled human serum albumin-dithiosemicarbazone (62Cu-HSA-DTS) as a blood-pool imaging agent for PET. To evaluate 62Cu-HSA-DTS for plasma-pool imaging and to measure the regional cerebral hematocrit, 12 normal volunteers and 7 patients with cerebrovascular disease underwent PET studies with 62Cu-HSA-DTS and 15O-labeled carbon monoxide (C15O).
METHODS: The normal subjects were studied with both C15O and 62Cu-HSA-DTS. All patients were examined by 15O-gas studies to measure cerebral perfusion and oxygen metabolism, followed by measurement of plasma volume with 62Cu-HSA-DTS for analysis of regional cerebral hematocrit. Regional cerebral hematocrit was calculated from regional cerebral red cell volume (rCRCV) measured by C15O and regional plasma volume (rCPV) measured by 62Cu-HSA-DTS in each subject, and the regional cerebral/large-vessel hematocrit ratio was obtained for both cerebral hemispheres in each subject.
RESULTS: Mean regional cerebral hematocrit and mean cerebral/large-vessel hematocrit ratio in the 12 normal volunteers were 38.3 +/- 3.45% and 0.88 +/- 0.06, respectively. In the seven patients with cerebrovascular disease, regional cerebral hematocrit was significantly lower on the hypoperfused side than the normal hemisphere. The images of rCPV and rCRCV from these patients demonstrated a greater increase in rCPV than rCRCV in the hypoperfused area.
CONCLUSION: These results suggest that 62Cu-HSA-DTS can be used for measurement of plasma volume and that regional cerebral hematocrit may provide valuable information regarding the microcirculation in the brain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8965173

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

1.  The new FDG brain revolution: the neurovascular unit and the default network.

Authors:  Stelvio Sestini; Antonio Castagnoli; Luigi Mansi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05       Impact factor: 9.236

2.  In Vivo Labeling of Serum Albumin for PET.

Authors:  Gang Niu; Lixin Lang; Dale O Kiesewetter; Ying Ma; Zhongchan Sun; Ning Guo; Jinxia Guo; Chenxi Wu; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2014-05-19       Impact factor: 10.057

3.  Clinical Translation of an Albumin-Binding PET Radiotracer 68Ga-NEB.

Authors:  Jingjing Zhang; Lixin Lang; Zhaohui Zhu; Fang Li; Gang Niu; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2015-08-06       Impact factor: 10.057

4.  CBF/CBV maps in normal volunteers studied with (15)O PET: a possible index of cerebral perfusion pressure.

Authors:  Tadashi Watabe; Eku Shimosegawa; Hiroki Kato; Kayako Isohashi; Mana Ishibashi; Jun Hatazawa
Journal:  Neurosci Bull       Date:  2014-08-01       Impact factor: 5.203

5.  A novel approach to measure local cerebral haematocrit using MRI.

Authors:  Fernando Calamante; André Ahlgren; Matthias J P van Osch; Linda Knutsson
Journal:  J Cereb Blood Flow Metab       Date:  2015-09-30       Impact factor: 6.200

6.  Assessment of infant brain development with frequency-domain near-infrared spectroscopy.

Authors:  Maria Angela Franceschini; Sonal Thaker; George Themelis; Kalpathy K Krishnamoorthy; Heather Bortfeld; Solomon G Diamond; David A Boas; Kara Arvin; P Ellen Grant
Journal:  Pediatr Res       Date:  2007-05       Impact factor: 3.756

Review 7.  Quantification of brain oxygen extraction and metabolism with [15O]-gas PET: A technical review in the era of PET/MRI.

Authors:  Audrey P Fan; Hongyu An; Farshad Moradi; Jarrett Rosenberg; Yosuke Ishii; Tadashi Nariai; Hidehiko Okazawa; Greg Zaharchuk
Journal:  Neuroimage       Date:  2020-07-04       Impact factor: 6.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.